调节性 T 细胞清除 cDC1 细胞会危及癌症免疫治疗。
Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy.
机构信息
Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
出版信息
Oncoimmunology. 2024 Oct 4;13(1):2412874. doi: 10.1080/2162402X.2024.2412874. eCollection 2024.
Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (T1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.
最近的研究结果表明，新抗原特异性细胞毒性 T 细胞 1 型调节性 T（T1）CD4 T 细胞可以通过杀死呈递与 MHC Ⅱ类结合的肿瘤抗原的 1 型常规树突状细胞（cDC1）来颠覆癌症免疫疗法。这凸显了 cDC1 在引发抗癌免疫中的重要性，但也带来了新的临床挑战。
Zotero 插件